Marksans Pharma

Marksans Pharma EPS

The Earnings per Share (EPS) of Marksans Pharma (MARKSANS.NS) as of Nov 18, 2026 is 8.40 INR. In the previous year, Earnings per Share (EPS) was 6.93 INR — a change of 21.28% (higher).

EPS

8.40INR

YoY

21.28%

Last updated:

Earnings per Share (EPS) of Marksans Pharma is 2025 8.40 INR. Earnings per Share (EPS) of Marksans Pharma was 2024 6.93 INR. It decreases by 21.28% higher compared to the previous year.

The Marksans Pharma EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2023
5.88 INR
Jan 1, 2024
6.93 INR
Jan 1, 2025
8.40 INR
Jan 1, 2026 (e)
8.57 INR
Jan 1, 2027 (e)
12.70 INR
Jan 1, 2028 (e)
14.00 INR
Jan 1, 2029 (e)
17.70 INR
Jan 1, 2030 (e)
20.40 INR
The Marksans Pharma EPS history
YEAREPSYoY
est20.40INR+15.25%
est17.70INR+26.43%
est14.00INR+10.24%
est12.70INR+48.25%
est8.57INR+1.93%
8.40INR+21.28%
6.93INR+17.93%
5.88INR+28.30%
4.58INR-20.53%
5.76INR+104.45%
2.82INR+53.51%
1.84INR+133.55%
0.79INR+278.76%
0.21INR-89.03%
1.89INR-29.49%
2.68INR+43.69%
1.87INR+56.68%
1.19INR-124.54%
-4.86INR-19.89%
-6.07INR+2,132.00%
-0.27INR+19.05%
-0.23INR-153.21%
0.43INR+126.47%
0.19INR-70.31%
0.64INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Marksans Pharma Stock analysis

What does Marksans Pharma do? Marksans Pharma Ltd. generates revenue through the research, manufacturing, marketing, and sale of pharmaceutical formulations across multiple therapeutic areas including pain management, cough and cold, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic products. The company operates four manufacturing facilities in India, the United Kingdom, and the United States, producing oral solid tablets, soft gelatin capsules, hard capsules, non-sterile liquids, ointments, and powders. Its products are distributed to markets in the United Kingdom, West Africa, and the Middle East, with manufacturing facilities in Goa, the United Kingdom, and the United States catering to these regions. The firm's primary revenue streams come from the sale of pharmaceutical formulations manufactured at its facilities in Goa, the United Kingdom, and the United States. The company's product portfolio spans various therapeutic segments, with manufacturing capabilities for tablets, capsules, liquids, ointments, and powders. Its facilities in Goa and the United Kingdom serve the United Kingdom, West Africa, and the Middle East markets, while the U.S. facility focuses on domestic and international distribution of tablet and capsule products. Marksans Pharma Ltd. sells its pharmaceutical formulations to healthcare providers, pharmacies, and distributors across multiple regions. The company's manufacturing facilities in Goa, the United Kingdom, and the United States support its global distribution network, with specific facilities dedicated to serving the United Kingdom, West Africa, and the Middle East markets through non-sterile liquid, ointment, and powder products. The firm's product range includes pain management, cough and cold, cardiovascular, and anti-diabetic formulations, among others, sold to customers in the specified regions. Marksans Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marksans Pharma stock

Earnings per Share (EPS) of Marksans Pharma is 8.40 INR in 2025.

Earnings per Share (EPS) of Marksans Pharma changed from 6.93 INR to 8.40 INR, representing a 21.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Marksans Pharma since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Marksans Pharma

All Key Metrics — Marksans Pharma